Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

Neurobiology of Aging

Volumn 33, Issue 6, 2012, Pages 1034-1044

  Bradley, Melissa A ^a   Xiong Fister, Shuling ^b   Markesbery, William R ^a,b   Lovell, Mark A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

4 Hydroxyhexenal; Alzheimer's disease (AD); Lipid peroxidation; Mild cognitive impairment (MCI); Neurodegenerative diseases; Preclinical Alzheimer's disease (PCAD)

Indexed keywords

4 HYDROXYHEXENAL; 4 HYDROXYNONENAL; ACROLEIN; AMYLOID BETA PROTEIN; GLUCOSE; HEXOBARBITAL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANATOMICAL VARIATION; ANIMAL CELL; ARTICLE; CEREBELLUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLUCOSE TRANSPORT; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MALE; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PARAHIPPOCAMPAL GYRUS; PATHOGENESIS; PRIORITY JOURNAL; RAT;

AGED; AGED, 80 AND OVER; ALDEHYDES; ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEURONS; RATS; UP-REGULATION;

EID: 84859510372     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.08.016     Document Type: Article

References (62)

1. Current Protocols in Immunology 2001, John Wiley, New York. J.S. Bonifacino, B. Bierer, D.H. Margulies, E.M. Shevach, W. Strober, R. Coico (Eds.).
2. Braak H., Braak E., Bohl J., Lang W. Alzheimer's disease: amyloid plaques in the cerebellum. J. Neurol. Sci 1989, 93:277-287.
3. Bradley M.A., Markesbery W.R., Lovell M.A. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer's disease (PCAD). Free Radic. Biol. Med 2010, 48:1570-1576.
4. Butterfield D.A., Reed T., Perluigi M., De Marco C., Coccia R., Cini C., Sultana R. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-noenal, in brain from persons with mild cognitive impairment. Neurosci. Lett 2006, 397:170-173.
5. Calingansan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem 1999, 72:751-756.
6. Chen J.J., Bertrand H., Yu B.P. Inhibition of adenine nucleotide translocator by lipid peroxidation products. Free Radic. Biol. Med 1995, 19:583-590.
7. Ding Q., Markesbery W.R., Cecarini V., Keller J.N. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem. Res 2006, 31:705-710.
8. Ding Q., Markesbery W.R., Chen Q., Keller J.N. Ribosome dysfunction Is an early event in Alzheimer's disease. J. Neurosci 2005, 25:9171-9175.
9. Drake J., Petroze R., Castegna A., Ding Q., Keller J.N., Markesbery W.R., Lovell M.A., Butterfield D.A. 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci. Lett 2004, 356:155-158.
10. Fitzmaurice P.S., Junchao T., Yazdanpanah M., Liu P.P., Kalasinsky K.S., Kish S.J. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J. Pharmacol. Exp. Ther 2006, 319:703-709.
11. Gabbita S.P., Lovell M.A., Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem 1998, 71:2034-2040.
12. Je H.H., Lee J.Y., Jung K.J., Sung B., Go E.K., Yu B.P., Chung H.Y. NF-kB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett 2004, 566:183-189.
13. Kawai Y., Fujii H., Okada M., Tsuchie U., Uchida K., Osawa T. Formation of nepsilon-(succinyl)lysine in vivo: a novel marker for docosahexaenoic acid-derived protein modification. J. Lipid Res 2006, 47:1386-1398.
14. Kristal B.S., Park B.K., Yu B.P. 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J. Biol. Chem 1996, 271:6033-6038.
15. Lee J.Y., Je J.H., Jung K.J., Yu B.P., Chung H.Y. Induction of endothelial iNOS by 4-hydroxyhexenal through NF-kappaB activation. Free Radic. Biol. Med 2004, 37:539-548.
16. Lee J.Y., Je J.H., Kim D.H., Chung S.W., Zou Y., Kim N.D., Yoo M.A., Baik H.S., Yu B.P., Chung H.Y. Induction of endothelial apoptosis by 4-hydroxyhexenal. Eur. J. Biochem 2004, 271:1339-1347.
17. Lim S.Y., Doherty J.D., Salem N. Lead exposure and (n-3) fatty acid deficiency during rat neonatal development alter liver, plasma, and brain polyunsaturated fatty acid composition. J. Nutr 2005, 135:1027-1033.
18. Liu Q., Smith M.A., Avila J., DeBernardis J., Kansal M., Takeda A., Zhu X., Nunomura A., Honda K., Moreira P.I., Oliveria C.R., Santos M.S., Shimohama S., Aliev G., de La Torre J., Ghanbari H.A., Siedlak S.L., Harris P.L.R., Sayre L.M., Perry G. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic. Biol. Med 2005, 38:746-754.
19. Long E.K., Murphy T.C., Leiphon L.J., Watt J., Morrow J.D., Milne G.L., Howard J.R.H., Picklo M.J. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J. Neurochem 2008, 105:714-724.
20. LoPachin R.M., Gavin T., Petersen D.R., Barber D.S. Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: nucleophilic targets and adduct formation. Chem. Res. Toxicol 2009, 22:1499-1508.
21. Lovell M.A., Xie C., Markesbery W.R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 1998, 51:1562-1566.
22. Lovell M.A., Gabbita S.P., Markesbery W.R. Increase DNA oxidation and decreased levels of repair products in Alzheimer's Disease ventricular CSF. J. Neurochem 1999, 72:771.
23. Lovell M.A., Xie C., Markesbery W.R. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic. Biol. Med 2000, 29:714-720.
24. Lovell M.A., Xie C., Markesbery W.R. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res 2000, 855:166-173.
25. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging 2001, 22:187-194.
26. Mark R.J., Pang Z., Geddes J.W., Uchida K., Mattson M.P. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci 1997, 17:1046-1452.
27. Markesbery W.R., Kyyscio R.J., Lovell M.A., Morrow J.D. Lipid Peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol 2005, 58:730-735.
28. Markesbery W.R., Lovell M.A. Four-Hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 1998, 19:33-36.
29. Markesbery W.R., Schmitt F.A., Kryscio R.J., Davis D.G., Smith C.D., Wekstein D.R. Neuropathologic substrate of mild cognitive impairment. Arch. Neurol 2006, 63:38-46.
30. McGarth L.T., McGleenon B.M., Brennan S., McColl D., McIlroy S., Passmore A.P. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. Q. J. Med 2001, 94:385-490.
31. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
32. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol 1994, 36:747-751.
33. Montine K.S., Olson S.J., Amarnath V., Whetsell W.O., Graham D.G., Montine T.J. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am. J. Pathol 1997, 150:437-443.
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
35. Murphy M.P., Beckett T.L., Ding Q., Patel E., Markesbery W.R., St Clair D.K., LeVine H., Keller J.N. A-beta solubility and deposition during AD progression and in APP x PS-1 knock-in mice. Neurobiol. Disord 2007, 27:301-311.
36. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol. Aging 1997, 18:S1-S2. NIA-Reagan Working Group.
37. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K. Oxidative damage is the earliest even in Alzhiemer's disease. J. Neuropathol. Exp. Neurol 2001, 60:759-767.
38. Pawlosky R.J., Bacher J., Salem N. Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: nutritional consequences of low n-3 fatty acid diet. Alcohol. Clin. Exp. Res 2001, 25:1758-1765.
39. Perez M., Cuadros R., Smith M.A., Perry G., Avila J. Phosphorylated, but not native, tau protein assembles following reaction with lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett 2000, 486:270-274.
40. Perez M., Hernandez F., Gomez-Ramos A., Smtih M., Perry G., Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cells. Eur. J. Biochem 2002, 269:1484-1489.
41. Peterson R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol 1999, 56:303-308.
42. Pocernich C.B., Butterfield D.A. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox. Res 2003, 5:515-520.
43. Pocernich C.B., Poon H.F., Boyd-Kimball D., Lynn B.C., Nath A., Klein J.B., Butterfield D.A. Proteomic analysis of oxidatively modified proteins induced by mitochondrial toxin 3-nitropropionic acid in human astrocytes expressing the HIV protein tat. Mol. Brain Res 2005, 133:299-306.
44. Reed T., Perluigi M., Sultana R., Pierce W.M., Klein J.B., Turner D.M., Coccia R., Markesbery W.R., Butterfield D.A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis 2008, 30:107-120.
45. Saiki R.K., Bugawan T.L., Horn G.T., Mukkis K.B., Erlich H.A. Analysis of enzymatically amplified beta-globin and hla-dq alpha DNA with allele-specific oligonucleotide probes. Nature 1986, 324:163-166.
46. Salem N.J., Litman B., Kim H.Y., Gawrisch K. Mechanisms of action of docosahexxaenoic acid in the nervous system. Lipids 2001, 36:945-959.
47. Schmitt F.A., Davis D.G., Wekstein D.R., Smith C.D., Ashford J.W., Markesbery W.R. "Preclincal" AD revisited: Neuropathology of cognitively older adults. Neurology 2000, 55:370-376.
48. Shan X., Tashiro H.L., Lin C.L. The identification and characterization of oxidized RNAs in Alzheimer's disease. J. Neurosci 2003, 23:4913. 2921.
49. Shao C., Xiong S., Guo-Min L., Gu L., Mao G., Markesbery W.R., Lovell M.A. Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic. Biol. Med 2008, 45:813-819.
50. Siesjo B.K., Ingvar M., Westerberg E. The influence of bicuculline-induced seizures on free fatty acid concentrations in cerebral cortex, hippocampus, and cerebellum. J. Neurochem 1982, 39:796-802.
51. Smith C.D., Chebrolu J., Markesbery W.R., Liu J. Improved predictive model for pre-symptomatic mild cognitive impairment and Alzheimer's disease. Neurol. Res 2008, 30:1091-1096.
52. Sultana R., Boyd-Kimball D., Poon H.F., Cai J., Peirce W.M., Klein J.B., Markesbery W.R., Zhou X.Z., Lu J.P., Butterfield D.A. Oxidative modfication and down-regulation of PinI in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol. Aging 2006, 27:1094.
53. Takeda A., Smith M.A., Avila J., Nunomura A., Siedlak S.L., Zhu X., Perry G., Sayre L.M. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitipe of tau induced by 4-hydroxy-2-nonenal modification. J. Neurochem 2000, 75:1234-1241.
54. Thomann P.A., Schlafer C., Seidl U., Santos V.D., Essig M., Schroder J. The cerebellum in mild cognitive impairment and Alzheimer's disease - a structural MRI study. J. Psychiatr. Res 2008, 42:1198-1202.
55. Van Kuijk F.J., Holte L.L., Dratz E.A. four-hydroxhexenal: a lipid peroxidation product derived from oxidized docosahexaenoic acid. Biochim. Biophys. Acta 1990, 1043:116-118.
56. Wang J., Markesbery W.R., Lovell M.A. Increase oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J. Neurochem 2006, 96:825-832.
57. Wataya T., Nunomura A., Smith M.A., Siedlak S.L., Harris P.L.R., Shimohama S., Szweda L.I., Kaminski M.A., Avila J., Price D.L., Cleveland D.W., Sayre L.M., Perry G. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J. Biol. Chem 2002, 277:4644-4648.
58. Wegiel J., Wisniewski H.M., Dziewiathkowski J., Badmajew E., Tarnawski M., Reisberg B., Mlodzik B., De Leon M.J., Miller D.C. Cellbellar atropy in Alzheimer's disease - clinicopathological correlations. Brain Res 1999, 818:41-50.
59. Williams T.I., Lynn B.C., Markesbery W.R., Lovell M.A. Increase levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging 2006, 27:1094-1099.
60. Xie C., Markesbery W.R., Lovell M.A. Survival of hippocampal and cortical neurons in a mixture of MEM+ and B-27 supplemented neurobasal medium. Free Radic. Bio. Med 2000, 28:665-672.
61. Yamaguchi H., Hirai S., Morimatsu M., Shoji M., Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol 1989, 77:314-319.
62. Zambrano C.A., Egana J.T., Nunez M.T., Maccioni R.B., Gonzalez-Billault C. Oxidative stress protomes tau dephosphorlation in neuronal cells: The roles of Cdk5 and PP1. Free Radic. Biol. Med 2004, 36:1393-1402.